Lp-PLA2, a new biomarker of vascular disorders in metabolic diseases.
Alessandro De StefanoLiliana MannucciFederica TamburiCarmine CardilloFrancesca SchinzariValentina RovellaSteven Paul NisticoLuigi BennardoNicola Di DanieleManfredi TesauroPublished in: International journal of immunopathology and pharmacology (2019)
Metabolic diseases are chronic disorders correlated to a greater risk of cardiovascular event and death. Recently, many data have sustained the biological link between microvascular dysfunction, oxidative stress, vascular inflammation, and metabolic diseases. The determination of new and specific blood biomarkers of vascular inflammation associated with obesity-related metabolic syndrome (MetS) and diabetes such as lipoprotein-associated phospholipase A2 (Lp-PLA2) could be useful to identify subject with high risk of cardiovascular events. Lp-PLA2 participates by a crucial role in microvascular dysfunction and oxidative stress showing positive association with metabolic disorders. In this review, we will argue the evolving role of Lp-PLA2 in predicting cardiovascular events in metabolic disease patients.
Keyphrases
- cardiovascular events
- oxidative stress
- metabolic syndrome
- coronary artery disease
- cardiovascular disease
- type diabetes
- end stage renal disease
- dna damage
- insulin resistance
- ejection fraction
- induced apoptosis
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- prognostic factors
- body mass index
- electronic health record
- adipose tissue
- artificial intelligence
- high fat diet induced
- patient reported outcomes
- glycemic control
- liquid chromatography